• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Soleno Therapeutics Inc.

    9/5/24 6:37:11 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email
    SC 13G 1 ea0213665-13gvivo_soleno.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.       )*

     

    Soleno Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    834203309

    (CUSIP Number)

     

    August 27, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.  

    NAMES OF REPORTING PERSONS  

     

    Vivo Opportunity Fund Holdings, L.P.

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ☐        (b)   ☒

    3.  

    SEC USE ONLY

     

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
       5.   

    SOLE VOTING POWER

     

    6,291,851 (1)

       6.  

    SHARED VOTING POWER

     

    0

       7.  

    SOLE DISPOSITIVE POWER

     

    6,291,851 (1)

       8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,291,851 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    16.2% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The shares of common stock, $0.001 par value (the “Common Stock”) of Soleno Therapeutics, Inc. (the “Issuer”) are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

    (2)The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 7, 2024.

     

    2

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ☐       (b)   ☒

    3.  

    SEC USE ONLY

     

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
       5.  

    SOLE VOTING POWER

     

    6,291,851 (1)

       6.  

    SHARED VOTING POWER

     

    0

       7.  

    SOLE DISPOSITIVE POWER

     

    6,291,851 (1)

       8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,291,851 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    16.2% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
    (2)The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

    3

     

     

    Explanatory Statement

     

    The Reporting Persons initially reported their beneficial ownership of the Issuer on a Schedule 13G filed with the SEC on May 15, 2023 and subsequently reported their beneficial ownership on a Schedule 13D originally filed with the SEC on June 1, 2023, as amended on October 11, 2023 and May 1, 2024 (the “Schedule 13D”). Pursuant to Rule 13d-1(h), the Reporting Persons are eligible to again report their beneficial ownership of shares of Common Stock of the Issuer on a Schedule 13G, and this Schedule 13G shall operate as an amendment to the Schedule 13D.

     

    Item 1. Issuer      
         
      (a) Name of Issuer:      
         
        Soleno Therapeutics, Inc. (the “Issuer”)      
         
      (b) Address of Issuer’s Principal Executive Offices:      
         
        203 Redwood Shores Pkwy, Suite 500
    Redwood City, CA 94065      
         
    Item 2. Filing Person      
         
      (a) – (c) Name of Persons Filing; Address; Citizenship:      

     

      (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and
         
      (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.

     

      (d) Title of Class of Securities:      
         
        Common Stock, par value $0.001 per share (“Common Stock”).       
         
      (e) CUSIP Number: 

    834203309      

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:   

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act;
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    4

     

     

      (j) ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.Ownership.

     

      (a) and (b) 

    Amount beneficially owned:

     

    The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.  

     

    (c)Number of shares as to which such person has:

     

    Reporting Person  Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Percentage of
    Common Stock
    Outstanding
     
    Vivo Opportunity Fund Holdings, L.P.   6,291,851    0    6,291,851    0    16.2%*
    Vivo Opportunity, LLC   6,291,851    0    6,291,851    0    16.2%*

     

    *The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.  

    Not applicable.   
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.      
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.  

    Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.  

    Not applicable.      
       
    Item 9. Notice of Dissolution of Group.  

    Not applicable.      
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 5, 2024

     

    VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
         
    By: Vivo Opportunity, LLC  
    Its: General Partner  
         
    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  
         
    VIVO OPPORTUNITY, LLC  
         
    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  

     

    6

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    99.1Joint Filing Statement

     

     

    7

     

     

    Get the next $SLNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    5/10/2024$72.00Outperform
    Robert W. Baird
    2/5/2024$93.00Overweight
    Piper Sandler
    1/23/2024$63.00Buy
    Stifel
    11/21/2023$40.00Buy
    Guggenheim
    More analyst ratings

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). "The validation of our MAA represents the next significant milestone in our mission to deliver this important therapy to the broad PWS communit

      5/22/25 5:32:41 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Participate in Upcoming June Conferences

      REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June: Jefferies Global Healthcare ConferencePresentation Date: Wednesday, June 4, 2025 at 10:30 AM ETPresentation Format: Corporate PresentationWebcast: Here Goldman Sachs 46th Healthcare ConferencePresentation Date: Tuesday, June 10, 2025 at 8:40 AM ETPresentation Format: Corporate PresentationWebcast: Here A replay of both events will be available in the Investors section on the Company's website at www.sol

      5/21/25 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms. "We

      5/20/25 4:05:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    See more
    • Soleno Therapeutics Set to Join Russell 3000® Index

      REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

      6/4/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Strengthens Leadership Team with Key Appointments

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

      1/24/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

      REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

      8/16/23 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Volck Birgitte was granted 3,991 shares, increasing direct ownership by 29% to 17,536 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      6/9/25 7:27:59 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Sinclair Andrew was granted 3,991 shares, increasing direct ownership by 61% to 10,491 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      6/9/25 7:25:16 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Pauls Matthew was granted 3,991 shares, increasing direct ownership by 61% to 10,491 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      6/9/25 7:21:26 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      9/28/23 3:45:22 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    SEC Filings

    See more
    • SEC Form 8-K filed by Soleno Therapeutics Inc.

      8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      6/6/25 4:06:30 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

      SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 12:02:12 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SCHEDULE 13G filed by Soleno Therapeutics Inc.

      SCHEDULE 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 10:45:26 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Financials

    Live finance-specific insights

    See more
    • Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

      5/7/25 4:01:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

      REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, May 7, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferenc

      4/23/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

      First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. begin

      3/26/25 5:15:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel resumed coverage on Soleno Therapeutics with a new price target

      Stifel resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      3/5/25 7:44:16 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stifel reiterated coverage on Soleno Therapeutics with a new price target

      Stifel reiterated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      12/2/24 10:10:09 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Robert W. Baird reiterated coverage on Soleno Therapeutics with a new price target

      Robert W. Baird reiterated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

      12/2/24 8:19:44 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/19/24 9:44:27 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 4:30:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 12:51:18 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care